Relay Therapeutics

Historical price data

Relay Therapeutics is a clinical-stage biotech company founded in 2016 with a mission to transform drug discovery by targeting protein dynamics. Its core achievement is the development of the Dynamo™ platform, which integrates computational and experimental biology to identify novel therapeutic mechanisms. The company's strategy is to leverage this platform to create highly selective small molecule drugs for precision oncology, with its lead candidate, RLY-4008, in pivotal development for FGFR2-altered cancers. Relay is publicly traded and aims to validate its motion-based drug design approach through clinical success.

The Dynamo™ platform integrates advanced computational simulations (molecular dynamics, machine learning) with leading-edge experimental techniques (Cryo-EM, X-ray crystallography) to visualize protein motion and enable the discovery of drugs targeting previously intractable or inadequately drugged proteins.